New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
07:22 EDTGILDGilead's single tablet Stribild shows positive results in two HIV studies
Gilead announced two-year results from two pivotal Phase 3 studies evaluating the company’s newest single tablet HIV regimen, StribildTM, among treatment-naïve patients with HIV-1 infection. Data show that Stribild was non-inferior after two years of treatment to two standard of care HIV regimens, Atripla in Study 102 and a protease-based regimen of ritonavir-boosted atazanavir plus Truvada in Study 103. The regimen was approved by the FDA on August 27 for use by treatment-naïve HIV-positive adults based on 48-week results from Studies 102 and 103. A marketing application for Stribild is currently under review in the European Union.
News For GILD From The Last 14 Days
Check below for free stories on GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent GILD news | >>
April 9, 2014
11:43 EDTGILDGilead defended by analysts after recent pullback
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
08:41 EDTGILDAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
07:56 EDTGILDGilead poised for strong earnings, says RW Baird
Subscribe for More Information
07:23 EDTGILDEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
April 7, 2014
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
08:31 EDTGILDGilead announecs FDA priority review designation for Ledipasvir/Sofosbuvir
Gilead Sciences announced that the U.S. Food and Drug Administration has granted priority review to the company’s New Drug Application for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead filed the NDA for LDV/SOF on February 10, and the FDA has set a target action date under the Prescription Drug User Fee Act of October 10. The FDA has also assigned LDV/SOF a Breakthrough Therapy designation.
April 4, 2014
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA MU GNK AMZN FB GILD MA NFLX
April 3, 2014
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
April 2, 2014
16:32 EDTGILDGilead Phase 3 sofosbuvir study meets primary efficacy endpoint
Gilead Sciences announced topline results from a Phase 3 clinical trial in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus infection. The study met its primary efficacy endpoint of superiority compared to a predefined historical control sustained virologic response rate. In the study, 97% of genotype 2 HCV-infected patients receiving 12 weeks of an all-oral regimen of sofosbuvir plus RBV achieved a sustained virologic response 12 weeks after completing therapy. Based on these trial results, Gilead anticipates submitting a New Drug Application for sofosbuvir to the Japanese Pharmaceutical and Medical Devices Agency by mid-2014
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
06:21 EDTGILDGilead shares attractive at current levels, says Citigroup
Citigroup views shares of Gilead as "cheap" at current levels and keeps a Buy rating on the name with a $96 price target. Citi expects Gilead to generate $117B in free cash flow over the next 10 years and have $100B by 2023.
<< 1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use